Effect of adalimumab dose escalation in patients with Crohn's disease
Not Applicable
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000023719
- Lead Sponsor
- Shiga University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients without intestinal mucosal lesion 2. Patients with active tuberculosis 3. Patients with demyelinating disease 4. Patients with chronic heart failure 5. Serum creatinine more than 2 mg/dl 6. Total bilirubin more than 2 mg/dl 7. AST or ALT more than 50 IU/l 8. Patients under pregnancy or breast-feeding 9. Patients who wishes to become pregnant 10. Less than 15 years old 11. Patients who has neoplasm 12. Patients who have psychoneurotic disorder 13. Patients who do not agree to join this study 14. When the doctor in charge feel that the patients are not suitable for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The relationships between adalimumab trough levels before dose escalation and clinical remission rate at 12 weeks or mucosal healing in 24 weeks
- Secondary Outcome Measures
Name Time Method